Allegro Ophthalmics to Present for the First Time the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the ASRS Annual Meeting 2019
Risuteganib Met Visual Acuity Primary Endpoint with Statistical Significance in U.S. Phase 2 Trial SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–#DME—Allegro Ophthalmics,…